Research Directory

Q2 stocks: Trial results, regulatory nods help European shares

Read more

European Commission highlights access, supply in pharma proposal

Read more

FDA guides on accelerated approvals in oncology

Read more

Stock values decline and companies restructure

Read more

Q4 2022 Stock Comment

Read more

New era for drug pricing in US

Read more

Biotech companies advised to conserve cash

Read more

Antibody-drug conjugates come to the fore

Read more

Stocks plummet in Q2 but biotech keeps innovating

Read more

Biotech values in broad decline

Read more